CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Shionogi & Co Ltd (Parent) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Shionogi & Co Ltd (Parent)
3-1-8, Dosho-machi, Chuo-ku
Phone: +81 662022161p:+81 662022161 OSAKA-SHI, OSK  541-0045  Japan Fax: +81 662299596f:+81 662299596
Business Summary
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The prescription drug business is engaged in the development of eight new drugs including hypercholesterolemia treatment drugs Crestor, antihypertensive drugs Ilbetan Family (Irbetan, Aimix, Iltra) and antidepressant drugs Sinbalta. The Company is engaged in the provision of information to contribute to medical care by maximizing its products. The over-the-counter (OTC) pharmaceutical business handles products tailored to customers' lifestyles. The in-vitro diagnostics business is engaged in the sale of products, as well as the provision of information on infectious diseases, cardiovascular diseases and allergic diseases. The Company mainly provides its products and services in Japan, Europe and North America markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20193/31/2019Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer, Representative Director IsaoTeshirogi 62 7/1/2022 4/1/2007
Vice Chairman of the Board TakukoSawada 68 7/1/2022 4/1/2011
Senior Executive Officer, Chief Director of Overseas Business Kojihanasaki 7/1/2021
11 additional Officers and Directors records available in full report.

Business Names
Business Name
C & O Pharmaceutical Tech (Holdings) Ltd
Pionnier
Shionogi & Co., Ltd.(Parent)
Shionogi Inc.
Tetra Therapeutics

General Information
Number of Employees: 3,596 (As of 3/31/2019)
Outstanding Shares: 290,106,592 (As of 2/10/2023)
Fax Number: +81 662299596


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, September 25, 2023